Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists

Abstract

This invention relates to pharmaceutical compositions and methods for treating (including managing) or preventing metabolic syndrome related conditions using one or more RARβ (e.g., RARβ2) agonists. Such conditions include, but are not limited to, diseases in pancreas, liver, kidney, testes, muscle, or adipose tissue, as well as other organs that are associated with high fat diet and/or vitamin A deficiency, as well as other conditions associated with abnormal level of triglyceride, cholesterol and/or glucose.

1 . A method of controlling cholesterol level and/or triglyceride level in a subject in need thereof, comprising administering to said subject vitamin A or a retinoic acid receptor-beta (RARβ) agonist. 
     
     
         2 . (canceled) 
     
     
         3 . A method of controlling glucose level, glucose intolerance, glucagon level and/or insulin sensitivity in a subject in need thereof, comprising administering to said subject vitamin A or a retinoic acid receptor-beta (RARβ) agonist. 
     
     
         4 .- 7 . (canceled) 
     
     
         8 . A method of treating or preventing fat accumulation in a subject in need thereof comprising administering to said subject vitamin A or a retinoic acid receptor-beta (RARβ) agonist. 
     
     
         9 .- 10 . (canceled) 
     
     
         11 . The method according to  claim 1 , wherein administration of said retinoic acid receptor-beta (RARβ) agonist treats or prevents a disease selected from the group consisting of a pancreatic disease, a cardiovascular disease, a liver disease, a kidney disease, obesity, fibrosis, hyperlipidemia, hypertriglyceridemia, hyperglycemia, or an organ-specific vitamin A deficiency. 
     
     
         12 . The method of  claim 11 , wherein said pancreatic disease is diabetes. 
     
     
         13 . The method of  claim 11 , wherein said liver disease is fatty liver disease (FLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, or hepatic steatosis. 
     
     
         14 . The method of  claim 11 , wherein said kidney disease is diabetic nephropathy. 
     
     
         15 . The method of  claim 11 , wherein said disease is associated with a high fat diet. 
     
     
         16 .- 17 . (canceled) 
     
     
         18 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is AC201066, AC55649 or a combination thereof. 
     
     
         19 . (canceled) 
     
     
         20 . The method according to  claim 1 , wherein said a retinoic acid receptor-beta (RARβ) agonist is administered three times daily. 
     
     
         21 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is administered at an amount from about 30 mg to about 200 mg per day. 
     
     
         22 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is administered at a concentration from about 0.1 mg to about 10 mg per 100 ml. 
     
     
         23 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is administered at a concentration from about 1 mg to about 3 mg per 100 ml. 
     
     
         24 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is administered orally. 
     
     
         25 . The method according to  claim 1 , wherein said retinoic acid receptor-beta (RARβ) agonist is administered intravenously or subcutaneously. 
     
     
         26 . The method according to  claim 1 , further comprising administering a second drug. 
     
     
         27 .- 37 . (canceled)